OBJECTIVES: The aim of this study was to determine the added value of the serum biomarkers S100 and neuron-specific enolase to clinical characteristics for predicting outcome after out-of-hospital cardiac arrest. BACKGROUND: Serum S100 beta (S100B) and neuron-specific enolase concentrations rise after brain injury. METHODS: A prolective observational study was conducted among all adult survivors of nontraumatic out-of-hospital cardiac arrest admitted to 1 hospital (April 3, 2008 to April 3, 2011). Three blood samples (on arrival and on days 1 and 3) were drawn for biomarkers, contingent on survival. Follow-up continued until in-hospital death or discharge. Outcomes were defined as good (Cerebral Performance Category score 1 or 2) or poor (Cerebral performance category score 3 to 5). RESULTS: A total of 195 patients were included (65.6% men, mean age 73 ± 16 years), with presenting rhythms of asystole in 61.5% and ventricular tachycardia or ventricular fibrillation in 24.1%. Only 43 patients (22.0%) survived to hospital discharge, 26 (13.3%) with good outcomes. Patients with good outcomes had significantly lower S100B levels at all time points and lower neuron-specific enolase levels on days 1 and 3 compared with those with poor outcomes. Independent predictors at admission of a good outcome were younger age, a presenting rhythm of ventricular tachycardia or ventricular fibrillation, and lower S100B level. Predictors on day 3 were younger age and lower day 3 S100B level. The area under the receiver-operating characteristic curve of the admission-day model was 0.932 with and 0.880 without biomarker data (p = 0.027 for the difference). CONCLUSIONS: Risk stratification after out-of-hospital cardiac arrest using both clinical and biomarker data is feasible. The biomarkers, although adding an ostensibly modest 5.2% to the area under the receiver-operating characteristic curve, substantially reduced the level of uncertainty in decision making. Nevertheless, current biomarkers cannot replace societal considerations in determining acceptable levels of uncertainty. (Protein S100 Beta as a Predictor of Resuscitation Outcome; NCT00814814).
OBJECTIVES: The aim of this study was to determine the added value of the serum biomarkers S100 and neuron-specific enolase to clinical characteristics for predicting outcome after out-of-hospital cardiac arrest. BACKGROUND: Serum S100 beta (S100B) and neuron-specific enolase concentrations rise after brain injury. METHODS: A prolective observational study was conducted among all adult survivors of nontraumatic out-of-hospital cardiac arrest admitted to 1 hospital (April 3, 2008 to April 3, 2011). Three blood samples (on arrival and on days 1 and 3) were drawn for biomarkers, contingent on survival. Follow-up continued until in-hospital death or discharge. Outcomes were defined as good (Cerebral Performance Category score 1 or 2) or poor (Cerebral performance category score 3 to 5). RESULTS: A total of 195 patients were included (65.6% men, mean age 73 ± 16 years), with presenting rhythms of asystole in 61.5% and ventricular tachycardia or ventricular fibrillation in 24.1%. Only 43 patients (22.0%) survived to hospital discharge, 26 (13.3%) with good outcomes. Patients with good outcomes had significantly lower S100B levels at all time points and lower neuron-specific enolase levels on days 1 and 3 compared with those with poor outcomes. Independent predictors at admission of a good outcome were younger age, a presenting rhythm of ventricular tachycardia or ventricular fibrillation, and lower S100B level. Predictors on day 3 were younger age and lower day 3 S100B level. The area under the receiver-operating characteristic curve of the admission-day model was 0.932 with and 0.880 without biomarker data (p = 0.027 for the difference). CONCLUSIONS: Risk stratification after out-of-hospital cardiac arrest using both clinical and biomarker data is feasible. The biomarkers, although adding an ostensibly modest 5.2% to the area under the receiver-operating characteristic curve, substantially reduced the level of uncertainty in decision making. Nevertheless, current biomarkers cannot replace societal considerations in determining acceptable levels of uncertainty. (Protein S100 Beta as a Predictor of Resuscitation Outcome; NCT00814814).
Authors: Alicia K Au; Michael J Bell; Ericka L Fink; Rajesh K Aneja; Patrick M Kochanek; Robert S B Clark Journal: Neurocrit Care Date: 2018-02 Impact factor: 3.210
Authors: Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas Journal: J Am Coll Cardiol Date: 2013-01-22 Impact factor: 24.094
Authors: Pascal Stammet; Josef Dankiewicz; Niklas Nielsen; François Fays; Olivier Collignon; Christian Hassager; Michael Wanscher; Johan Undèn; Jorn Wetterslev; Tommaso Pellis; Anders Aneman; Jan Hovdenes; Matt P Wise; Georges Gilson; David Erlinge; Janneke Horn; Tobias Cronberg; Michael Kuiper; Jesper Kjaergaard; Yvan Gasche; Yvan Devaux; Hans Friberg Journal: Crit Care Date: 2017-06-20 Impact factor: 9.097
Authors: Vinay Garg; Mark D Peterson; Michael Wa Chu; Maral Ouzounian; Roderick Gg MacArthur; John Bozinovski; Ismail El-Hamamsy; F Victor Chu; Ankit Garg; Judith Hall; Kevin E Thorpe; Natasha Dhingra; Hwee Teoh; Thomas R Marotta; David A Latter; Adrian Quan; Muhammad Mamdani; Peter Juni; C David Mazer; Subodh Verma Journal: BMJ Open Date: 2017-06-10 Impact factor: 2.692
Authors: William A Kofke; Yue Ren; John G Augoustides; Hongzhe Li; Katherine Nathanson; Robert Siman; Qing Cheng Meng; Weiming Bu; Sukanya Yandrawatthana; Guy Kositratna; Cecilia Kim; Joseph E Bavaria Journal: Front Neurol Date: 2018-06-26 Impact factor: 4.003